Skip to content

À la recherche de nouvelles avancées thérapeutiques et d'espoir grâce à des études cliniques au Québec

Les études cliniques représentent une passerelle essentielle dans la quête de nouveaux traitements médicaux et thérapies, offrant un phare d’espoir pour les patients luttant contre le sarcome au Québec. Ces études sont méticuleusement conçues pour évaluer l’efficacité, la sécurité et l’efficacité globale d’interventions médicales innovantes, telles que des médicaments et des vaccins, au sein d’une cohorte de participants humains. En évaluant rigoureusement ces interventions, les études cliniques veillent à ce qu’elles soient non seulement efficaces, mais aussi sûres pour une utilisation chez les patients atteints de sarcome.

La participation à des études cliniques joue un rôle central dans la propulsion de la communauté médicale sarcomateuse vers la découverte d’options de traitement révolutionnaires. Ces essais établissent de nouveaux critères dans les normes de soins, bénéficiant à la fois aux patients actuels et futurs. De plus, s’engager dans une étude clinique offre aux patients l’opportunité inestimable d’accéder à des traitements de pointe et ultramodernes qui pourraient autrement être hors de portée.

Ci-dessous, vous trouverez un tableau complet résumant la liste actuelle des études cliniques actives. Ces études tiennent la promesse de tracer un chemin plus lumineux dans la lutte contre le sarcome et offrent un nouvel espoir à ceux qui font face à cette redoutable maladie.

Études Cliniques menées par le groupe SaRC-Q

Nous vous invitons à explorer les études cliniques en cours menées par le groupe SaRC-Q. Si vous êtes intéressé(e) à participer à l’une de ces études novatrices, nous vous encourageons à en discuter avec votre oncologue. Pour entrer en contact avec l’investigateur de l’étude, n’hésitez pas à contacter le coordinateur.
Sarcoma SubtypeStudy Name & DescriptionPhaseSponsorParticipating HospitalsStatus
GISTAn International, Randomized, Multicenter, Open-label Study of Ripretinib vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumor (GIST) with KIT Exon 11 and Co-occurring KIT Exons 17 and/or 18 Mutations Who Were Previously Treated with Imatinib
(INSIGHT)
IIIDeciphera Pharmaceuticals LLCMUHCUpcoming
Advanced Dedifferentiated LiposarcomaAn Open-Label, Single-Arm, Multi-Center Study to Assess the Safety and Efficacy of Brigimadlin (BI 907828) Treatment in Patients with Treatment-naïve or Pre-treated Advanced Dedifferentiated LiposarcomaIIIBrightline-4/Boehringer IngelheimMUHCUpcoming
LeiomyosarcomaStudy of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)IIIPolaris PharmaceuticalsMUHCUpcoming
Advanced CancerA First in Human, Dose-Escalation Study of TORL-3-600 in Participants
with Advanced Cancer
ITORLMUHCUpcoming
Wild-type Solid TumorsAn Open-Label, Multi-Center Study to Investigate the Safety and Tolerability of SA53, an MDM2 Inhibitor, in Patients with Locally Advanced or Metastatic p53 Wild-type Solid Tumors (ACADIA)I
PI initiated MUHC
Upcoming
Advanced Solid TumorsTAK-676-1002 An Open-Label, Dose Escalation Study to Evaluate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of TAK-676 As A Single Agent And In Combination With Pembrolizumab in Adult Patients With Advanced Solid TumorsITakedaJewish General Hospital
McGill University Health Centre
Upcoming
GISTPeak
A randomized trial of CGT9486+Sunitinib vs. Sunitinib in subjects with gastrointestinal stromal tumors
IIICogent BiosciencesMaisonneuve-Rosemont Hospital (HMR)Active
Open for recruitment
Tenosynovial Giant Cell TumorA Randomized, Double-blind, Placebo-Controlled, Multicenter Study of ABSK021 to Assess the Efficacy and Safety in Patients with Tenosynovial Giant Cell TumorIIIAbbisko TherapeuticsMUHCActive
Open for recruitment
RhabdomyosarcomaCOG-ARST2031
A Randomized Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy With Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO Maintenance in Patients With High Risk Rhabdomyosarcoma (HR-RMS)
IIIChildren’s Oncology GroupMUHC
CHU Sainte-Justine
CHUQ
Active
Open for recruitment
Retroperitoneal Sarcoma A Randomized Study of Neoadjuvant Chemotherapy Followed by Surgery versus Surgery Alone for Patients with High Risk Retroperitoneal Sarcoma (STRASS2)IIICCTG SR.7Maisonneuve-Rosemont Hospital (HMR)
MUHC
Active
Advanced Solid TumorsA Phase 1a/B Open-Label Master Study of Pf-07799544 As A Single-Agent And In Combination With Other Targeted Agents In Participants With Advanced Solid TumorsIPfizerJewish General Hospital
McGill University Health Centre
Centre intégré de cancérologie du CHU de Québec
Université Laval, Hôpital de l’Enfant-Jésus
Active
LeiomyosarcomaSUNRISE-LMS
A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)
II-IIIPTC TherapeuticsMaisonneuve-Rosemont Hospital (HMR)Active
Closed for recruitment
Dedifferentiated LiposarcomaBrightline-1
A Study to Compare BI 907828 With Doxorubicin in People With Dedifferentiated Liposarcoma
II-IIIBoehringer IngelheimMaisonneuve-Rosemont Hospital (HMR)Active
Closed for recruitment
GISTINTRIGUE
A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib
IIIDeciphera Pharmaceuticals LLCMaisonneuve-Rosemont Hospital (HMR)Active
Closed for recruitment
Desmoid TumorsA Randomized, Double-Blind, Placebo-Controlled Trial of Nirogacestat versus Placebo in Adult Patients with Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)IIISpring Works TherapeuticsMUHCActive
Closed for recruitment
Synovial Sarcoma
Myxoid Liposarcoma
IGNYTE-ESO
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors
IIGlaxoSmithKlineMaisonneuve-Rosemont Hospital (HMR)Active
Closed for recruitment
Synovial Sarcoma
Myxoid Liposarcoma
ZENITH-ESO
Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors
IGlaxoSmithKlineMaisonneuve-Rosemont Hospital (HMR)Active
Closed for recruitment
Tenosynovial Giant Cell TumorA Multicenter Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors and Tenosynovial Giant Cell TumorI-IIDeciphera Pharmaceuticals LLCMUHCActive
Closed for recruitment
Soft Tissue SarcomaA randomized controlled trial of Neoadjuvant Pembrolizumab with Radiotherapy and Adjuvant Pembrolizumab in patients with high-risk localized soft tissue sarcoma of the extremityIISARCMUHCActive
On hold
RhabdomyosarcomaARST-1431
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
IIINational Cancer Institute (NCI)MUHC
CHU Sainte-Justine
Closed